189 related articles for article (PubMed ID: 38193476)
1. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
5. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
6. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
[TBL] [Abstract][Full Text] [Related]
7. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
Hong JH; Woo IS
Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
11. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
12. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
[TBL] [Abstract][Full Text] [Related]
14. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C
Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Thomas J; Leal A; Overman MJ
Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
18. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
Jin Z; Sinicrope FA
J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
20. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
